Only a handful of people realize this- but VRAL seriously does have
the most likely chance to become the next DNDN among all small cap
biotechnology stocks.

Consider the following facts:

(1) VRAL scientific advisory team consists of the 2008 Nobel Prize
Winner for Medicine (Dr. Luc Montgainer), a former U.S. Surgeon
General (Dr. C Everett Koop), specialists at Harvard Medical School
(Dr. Eric Rosenberg) and Marshall Phelps, Jr. (Microsoft’s lead IP/
Patent attorney)

(2) The VGV-1 injectable drug has successfully completed Phase 1-3
trials in South Africa for the treatment of HIV/AIDS and has proven
statistically verifiable results that confirm both the drugs safety
and effectiveness in treating the HIV virus. Since Phases 1-3 have
already been completed overseas, one could assume an FDA approval for
the use of VGV-1 would be fast tracked.

(3) The CEO of VRAL (Haig Keledjian) is a very passionate scientist,
not a businessman. He has been running VRAL since 1995 and is
certainly not running a fly-by-night operation. He’s in it for the
long term successful completion of FDA approvals for VGV-1.

(4) The mechanism of action for the VGV-1 injectable drug has been
discovered by one of the most prominent Pharmacologists in the nation,
Dr. Karen Newell from the University of Colorado.

(5) The injectable VGV-1 drug appears to have other autoimmune
applications including the usage of the drug for treatment of Lyme’s
Disease. VRAL has been awarded two separate grants for the R&D of
VGV-1 usage to treat Lyme’s Disease. Since the mechanism of action
involves the immune system and could potentially treat a variety of
autoimmune diseases, VRAL is pursuing a separate patent for each
unique VGV-1 treatment (i.e. one patent for HIV/AIDS treatment, one
patent for Lyme’s Disease treatment, etc) which allows for a number of
different revenue streams moving forward.

(6) Not only has the VGV-1 injectable drug proven its effectiveness in
Phase 1-3 trials in South Africa, but it is substantially more cost
effective than alternative HAART drugs. Whereas current HAART oral
drugs must be taken for life, the VGV-1 injectable drug is
administered through 16 intra-muscular injections over an eight week
period.

(7) VRAL’s CEO Haig Keledjian personally told me that he believes
their IND will be filed by the end of Q3 and that FDA Phase 1 trials
will begin before the end of 2009.

(8) VRAL has successfully completed 5 clinical trials for the use of
VGV-1 as an HIV/AIDS treatment and has proven statistically
significant results.

VRAL is a sleeper for sure, but its only a matter of time before Haig
Keledjian gets IND approval for VGV-1 and begins Phase I trials in the
United State (Q4).

Once that happens we’re looking at a $0.25-$0.50 without a doubt and I
think these may be conservative estimates given how hot the biotech
sector has been lately.